TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: IgE-binding capacity of selected proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24 h energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of peptic ulcer rebleeding
Endpoint domain: Mortality/survival
Primary endpoint: self-reported pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global treatment tolerance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preterm birth (PTB) between 28 and 31 weeks plus 6 days
Endpoint domain: Mortality/survival
Primary endpoint: Neonatal Intensive Care Unit (NICU) admissions
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal morbidity and mortality
Endpoint domain: Adverse events/effects
Primary endpoint: Ea improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ea/Ees improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: waking cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gain in BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: development in total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: development in language area
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: development in psycho-social and relational areas
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Minimum Transmyocardial Perfusion Reserve (TPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid overdose knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overdose risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscular strength of the upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of solid component in nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of semiautomatic and manual measurements of solid component diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total proximal femur BMD changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of overt type 2 diabetes mellitus
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic Blood Pressure (SBP) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum hepatitis delta virus RNA no longer detectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological activity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restless legs symptoms at night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Immobility at night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percent body fat (PBF) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic capacity improvement (12MWRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of signs and symptoms of lichen sclerosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean peak inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in Lequesnes index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall in visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain easement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-coagulation control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retinal detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Loss of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Graft survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Peak plasma concentration of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of wound leakage
Endpoint domain: Adverse events/effects
Primary endpoint: total body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in Der p 1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDM-induced early-reaction (ER) in the airways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of blood eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in pain intensity and abnormal sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased dependence on pain medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Faster epithelial healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy long-term survival
Endpoint domain: Mortality/survival
Primary endpoint: Mild neurodevelopmental delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 1RMest improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CMJ improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sprint time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma concentrations of ceftaroline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (rash/drug eruption)
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive ability to self-care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Service engagement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Involuntary readmissions
Endpoint domain: Adverse events/effects
Primary endpoint: perceived life stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cervical neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MVPA outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting plasma triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Boosting immune responses against poliovirus types 1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median antibody titers increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: composite of death, shock, or heart failure
Endpoint domain: Mortality/survival
Primary endpoint: door-to-PCI time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitral E/A values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tricuspid E deceleration time values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular Em values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of visible thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase of TIMI flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postpartum weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of antimicrobial drug usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apathy Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Seroprotective antibody titer (≥10 IU/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anamnestic response to challenge dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: wound infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: wound dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased aortic regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adolescent daily smoking rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total aerobic facultative counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive cultures obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: intramural bacteria observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMA score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhea incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALRI incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of methacholine required to cause a 20% drop in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AQLQ mean score units
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: neurobehavioral test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-assessed pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with health care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6MWT deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FVC upright deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant mortality after 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Time to first successful spontaneous breathing trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to successful extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel revascularisation (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: optimal response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grades 3-4 leukopenia
Endpoint domain: Adverse events/effects
Primary endpoint: neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Live births
Endpoint domain: Mortality/survival
Primary endpoint: Mild hypoglycemia rate/month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severe hypoglycemic (SH) events
Endpoint domain: Adverse events/effects
Primary endpoint: De-enrolment within 60 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fasting morning leptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reported food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: in-segment late loss (LL) at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent late loss (LL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of dysglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum SAH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum MMA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total homocysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delivery of a viable infant
Endpoint domain: Mortality/survival
Primary endpoint: Venous thromboembolism occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Pain free squat angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) increase in lateral region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of disorganized attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic and fissure healing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SFMPQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ODI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg serological negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perpetrator-punishment scale agreement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean improvement in functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: increase in skin elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction in wrinkle counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: increase in skin firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of IL-12 positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of IL-10 positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 12-month WOMAC pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage decrease of total serum bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defocus curve profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Direct bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Onset time of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of complete motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Connection Test performance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting venous blood ammonia concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Portosystemic Encephalopathy Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rise in Hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean increase in Mean Corpuscular Volume (MCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean decrease in Red Cell Distribution Width (RDW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Silness and Löe index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 levels in crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: role disability due to emotional problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: decreased risk for depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastric Transit Time (GTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Small Bowel Transit Time (SBTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient satisfaction with the outcome of multidisciplinary treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of cataracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Progression of cataracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Cumulative success rate of implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of rifapentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm birth < 35 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Neonatal morbidity index
Endpoint domain: Physiological/clinical
Primary endpoint: Fetal/early infant death
Endpoint domain: Mortality/survival
Primary endpoint: Keratinized tissue thickness gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of French fries and potato chips
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost reductions per successfully treated case
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Median progression-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Improvement on the MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on AES-clinician and -informant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operating time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative quality of life outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of postoperative and chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accumulated urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Levels of glutamate/creatine plus phosphocreatine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: less distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fewer anxious/depressive problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fewer dependency problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment response to corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VAS decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parturient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30-day postdialysis mortality
Endpoint domain: Mortality/survival
Primary endpoint: Major and minor bleeding ratios
Endpoint domain: Adverse events/effects
Primary endpoint: Intragastric pH at ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diet composition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced depression rate (HADS‐D score <8 at month 12)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Marginal peri-implant bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of OAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of OAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of OAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ovulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: rate of spontaneous abortion
Endpoint domain: Adverse events/effects
Primary endpoint: Mean cIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes